Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) CFO Thomas Patrick Kelly sold 5,000 shares of the firm’s stock in a transaction on Monday, January 7th. The stock was sold at an average price of $25.18, for a total transaction of $125,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
NASDAQ:DCPH opened at $24.92 on Friday. The firm has a market capitalization of $956.97 million, a PE ratio of -8.33 and a beta of 3.38. Deciphera Pharmaceuticals Inc has a 1-year low of $18.55 and a 1-year high of $45.61. The company has a current ratio of 18.46, a quick ratio of 18.46 and a debt-to-equity ratio of 0.06.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings data on Thursday, November 8th. The company reported ($0.65) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.65). Research analysts predict that Deciphera Pharmaceuticals Inc will post -2.62 EPS for the current fiscal year.
A number of research analysts have issued reports on DCPH shares. Leerink Swann decreased their price target on shares of Deciphera Pharmaceuticals from $28.00 to $20.00 and set an “underperform” rating for the company in a report on Friday, November 16th. BidaskClub raised shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 1st. Zacks Investment Research raised shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $27.00 price target for the company in a report on Tuesday. ValuEngine raised shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 2nd. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $53.00 price target on shares of Deciphera Pharmaceuticals in a report on Thursday, December 20th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $42.67.
Several large investors have recently added to or reduced their stakes in the company. Orbimed Advisors LLC increased its stake in shares of Deciphera Pharmaceuticals by 30.8% in the second quarter. Orbimed Advisors LLC now owns 2,005,700 shares of the company’s stock worth $78,924,000 after acquiring an additional 472,800 shares during the period. Redmile Group LLC increased its stake in shares of Deciphera Pharmaceuticals by 79.9% in the second quarter. Redmile Group LLC now owns 1,477,080 shares of the company’s stock worth $58,123,000 after acquiring an additional 655,800 shares during the period. FMR LLC increased its stake in shares of Deciphera Pharmaceuticals by 33.5% in the second quarter. FMR LLC now owns 1,182,091 shares of the company’s stock worth $46,515,000 after acquiring an additional 296,571 shares during the period. Emerald Advisers Inc. PA increased its stake in shares of Deciphera Pharmaceuticals by 19.0% in the third quarter. Emerald Advisers Inc. PA now owns 704,514 shares of the company’s stock worth $27,279,000 after acquiring an additional 112,290 shares during the period. Finally, Janus Henderson Group PLC increased its stake in shares of Deciphera Pharmaceuticals by 21.6% in the third quarter. Janus Henderson Group PLC now owns 679,498 shares of the company’s stock worth $26,310,000 after acquiring an additional 120,683 shares during the period. Hedge funds and other institutional investors own 55.04% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Deciphera Pharmaceuticals Inc (DCPH) CFO Thomas Patrick Kelly Sells 5,000 Shares” was originally reported by Zolmax and is the property of of Zolmax. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://zolmax.com/investing/deciphera-pharmaceuticals-inc-dcph-cfo-thomas-patrick-kelly-sells-5000-shares/2820469.html.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Featured Story: Investing strategies using the yield curve
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.